Trial · NCT07497854
A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
NCT07497854, Not yet recruiting, Pfizer
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea. Trials, record NCT07497854. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07497854
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea
- NCT number
- NCT07497854
- Status
- Not yet recruiting
- Enrollment
- 3,000 participants, estimated
- Lead sponsor
- Pfizer
- Conditions
- Migraine With or Without Aura
- Interventions
- Rimegepant sulfate
- First posted
- 2026-03-27
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | All adverse events (AEs) Unit of Measure: Number of participants with AEs |
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | Serious Adverse Events (SAEs) Unit of Measure : Number of participants with SAEs |
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | Expected Adverse Events (Expected AEs) Unit of Measure : Number of participants with Expected AEs |
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | Adverse Drug Reactions (ADRs) Unit of Measure : Number of participants with ADRs |
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | Serious Adverse Drug Reactions (SADRs) Unit of Measure : Number of participants with SADRs |
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | Unexpected Adverse Events (Unexpected AEs) Unit of Measure : Number of participants with Unexpected AEs |
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | Expected Adverse Drug Reactions (Expected ADRs) Unit of Measure : Number of participants with Expected ADRs |
| Primary | To evaluate the safety of NURTEC® ODT 75 mg (Rimegepant sulfate) in adult patients with acute treatment of migraine with or without aura and with preventive treatment of episodic migraine. | 28 days after from last administration of NURTEC® ODT 75 mg (Rimegepant sulfate) | Unexpected Adverse Drug Reactions (Unexpected ADRs) Unit of Measure : Number of participants with Unexpected ADRs |
| Secondary | Acute Treatment Effectiveness : Pain Free at 2 Hours | 2 hours post-dose | Percentage of subjects who are pain-free at 2 hours post-dose for the treatment of an acute migraine attack. Unit of Measure: Percentage of participants (%) |
| Secondary | Preventive Treatment Effectiveness : Change in Monthly Migraine Days (MMDs) | Baseline, 3 months, 6 months | Mean change from baseline in the number of Monthly Migraine Days (MMDs). Unit of Measure: Days |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07497854
GET https://conductscience.org/api/trials/v1/NCT07497854/registered